Core Insights - Aptevo Therapeutics Inc. (APVO) experienced a significant stock increase of 46.10% to $2.06 after reporting breakthrough clinical results for its drug aimed at treating acute myeloid leukemia (AML) [1] Clinical Trial Results - The Phase 1b/2 RAINIER trial showed a perfect remission rate, with all patients in Cohort 3 achieving complete remission using mipletamig in combination with venetoclax and azacitidine [2] - No dose-limiting toxicities or cytokine release syndrome were reported across all cohorts of the trial, indicating a favorable safety profile [2] Market Opportunity and Future Steps - The frontline AML market represents a multi-billion-dollar opportunity, with current standard treatments yielding lower remission rates compared to those observed in the RAINIER trial [3] - 40% of patients in the trial achieved minimal residual disease-negative status, which is a positive indicator for prognosis [3] - Enrollment for Cohort 4 is ongoing at higher dose levels, with a conference presentation anticipated in the fourth quarter [3] Stock Performance Overview - APVO's stock has seen a decline of approximately 31.9% from its one-month peak of $2.07 to a close of $1.41 [4] - Over the past year, the stock has decreased by 98.84%, and it is down 98.36% year-to-date in 2025 [4] - The clinical-stage stock has an annual trading range between $1.32 and $381.10, with a market capitalization of $4.64 million and an average trading volume of 3.98 million shares [4]